Intrauterine devices and pelvic inflammatory disease

Current Women's Health Reports

Volumn 3, Issue 4, 2003, Pages 280-287

  Gareen, Ilana F ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

CLINICAL STUDY; CONTRACEPTION; DISEASE ASSOCIATION; EQUIPMENT DESIGN; INFECTION RISK; INTRAUTERINE CONTRACEPTIVE DEVICE; PELVIC INFLAMMATORY DISEASE; REVIEW; ARTICLE; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; METHODOLOGY; MICROBIOLOGY; OUTCOME ASSESSMENT; REFERENCE VALUE; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; STATISTICS;

FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRAUTERINE DEVICES; OUTCOME ASSESSMENT (HEALTH CARE); PELVIC INFLAMMATORY DISEASE; REFERENCE VALUES; RESEARCH DESIGN; RISK FACTORS; SELECTION BIAS; SEXUALLY TRANSMITTED DISEASES;

EID: 0141497983     PISSN: 15345874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Gareen I, Greenland S, Morgenstern H: Intrauterine devices and pelvic inflammatory disease: meta-analyses of published studies, 1974-1990. Epidemiology 2000, 11:589-597.
2. Dardano KL, Burkman RT: The intrauterine contraceptive device: an often-forgotten and maligned method of contraception. Am J Obstet Gynecol 1999, 181:1-5.
3. Grimes DA: Intrauterine device and upper-genital-tract infection. Lancet 2000, 356:1013-1019.
4. Grimes DA, Hubacher D: IUDs: time for a renaissance. Am Fam Physician 1998, 58:1963-1964.
5. Kimble-Haas SL: The intrauterine device: dispelling the myths. Nurse Pract 1998, 23:58, 63-69, 73.
6. Westhoff CL: Current assessment of the use of intrauterine devices. J Nurse Midwifery 1996, 41:218-223.
7. Rivera R, Best K: Current opinion: consensus statement on intrauterine contraception. Contraception 2002, 65:385-388.
8. Lee NC, Rubin GL, Ory W, Burkman RT: Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol 1983, 62:1-6.
9. Lee NC, Rubin GL, Borucki R: The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet Gynecol 1988, 72:1-6.
10. American College of Obstetrics and Gynecology: Intrauterine device. ACOG Technical Bulletin 164 - February 1992 (replaces 104, May 1987). Int J Gynaecol Obstet 1993, 41:189-193.
11. Batar I, Kuukankorpi A, Siljander M, et al.: Five-year clinical experiences with NOVA T 380 copper IUD. Contraception 2002, 66:309-314.
12. Dubuisson JB, Mugnier E: Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002, 66:121-128.
13. Cox M, Tripp J, Blacksell S: Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network. 5-year report. J Fam Plann Reprod Health Care 2002, 28:73-77.
14. Cox M, Tripp J, Blacksell S: Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002, 28:69-72.
15. Cao X, Zhang W, Gao G, et al.: Randomized comparative trial in parous women of the frameless GyneFix and the TCu380A intrauterine devices: long-term experience in a Chinese family planning clinic. Eur J Contracept Reprod Health Care 2000, 5:135-140.
16. Wu S, Hu J, Wildemeersch D: Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women. Contraception 2000, 61:91-98.
17. Lete I, Morales P, de Pablo JL: Use of intrauterine contraceptive devices in milliparous women: personal experience over a 12-year period. Eur J Contracept Reprod Health Care 1998, 3:190-193.
18. Reinprayoon D, Gilmore C, Farr G, Amatya R: Twelve-month comparative multicenter study of the TCu380A and ML 250 intrauterine devices in Bangkok, Thailand. Contraception 1998, 58:201-206.
19. Sarma SP, Garafalo K, Graves WL: Use of the intrauterine device by inner-city women. Arch Fam Med 1998, 7:130-133.
20. Baeyertz JD, Hartfield VJ: The Nova-T 200 intrauterine contraceptive device: a 12-year study. N Z Med J 1997, 110:169-171.
21. Khomassuridze AG, Tsertsvadze GL, Tsereteli TG: Intrauterine device and pelvic inflammatory disease. Adv Contracept 1997, 13:71-78.
22. UN Development Programme: Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997, 56:341-352.
23. Duenas JL, Albert A, Carrasco F: Intrauterine contraception in nulligravid vs parous women. Contraception 1996, 53:23-24.
24. Morrison C, Waszak C, Katz K, et al.: Clinical outcomes of two early postpartum IUD insertion programs in Africa. Contraception 1996, 53:17-21.
25. Rosenberg MJ, Foldesy R, Mishell DR Jr, et al.: Performance of the TCu380A and Cu-Fix IUDs in an international, randomized trial. Contraception 1996, 53:197-203.
26. Arowojolu AO, Otolorin EO, Ladipo CA: Performances of copper T 380A and multiload copper 375/250 intrauterine contraceptive devices in a comparative clinical trial. Afr J Med Sci 1995, 24:59-65.
27. Rubin GL, Ory HW, Layde PM: Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982, 144:630-635.
28. Kelaghan J, Rubin GL, Ory HW, Layde PM: Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982, 248:184-187.
29. Farley TMM, Rosenberg MJ, Rowe PJ, et al.: Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992, 339:785-788.
30. Greenland S: Meta-analysis. In Modern Epidemiology, edn 2. Edited by Rothman KJ, Greenland S. Philadelphia: Lippincott-Raven Publishers, 1998:643-673.
31. Skegg DC: Evaluating the safety of medicines, with particular reference to contraception. Stat Med 2001, 20:3557-569.
32. Kani J, Adler MW: Epidemiology of pelvic inflammatory disease. In Pelvic Inflammatory Disease. Edited by Berger GS, Westrom LV. New York, NY: Raven Press; 1992:7-20.
33. Grodstein F, Rothman KJ: Epidemiology of pelvic inflammatory disease. Epidemiology 1994, 5:234-242.
34. Kronmal RA, Whitney CW, Mumford SD: The intrauterine device and pelvic inflammatory disease: the women's health study reanalyzed. J Clin Epidemiol 1991, 44:109-122.
35. Edelman DA, Berger GS, Keith L: The use of IUDs and their relationship to pelvic inflammatory disease: a review of epidemiologic and clinical studies. Curr Probl Obstet Gynecol 1982, 6:1-62.
36. Mumford SD, Kessel E. Was the Dalkon Shield a safe and effective intrauterine device? The conflict between case-control and clinical trial study findings. Fertil Steril 1992, 57:1151-1176.
37. Teitze C, Lewit S: Recommended procedures for the statistical evaluation of intrauterine contraception. Stud Fam Plann 1972, 4:35-42.
38. Berger GS, Westrom LV, Wolner-Hanssen P: Definition of pelvic inflammatory disease. In Pelvic Inflammatory Disease. Edited by Berger GS, Westrom LV. New York, NY: Raven Press; 1992:1-6.
39. Vessey MP, Doll HA: Copper intrauterine devices and tubal infertility among nulligravid women. N Engl J Med 2002, 346:376-377.
40. Washington AE, Arno PS, Brooks MA: The economic cost of pelvic inflamatory disease. JAMA 1986, 255:1735-1738.
41. Jossens MO, Schachter J, Sweet RL: Risk factors associated with pelvic inflammatory disease of differing microbial etiologies. Obstet Gynecol 1994, 83:989-997.
42. Merki-Feld GS, Lebeda E, Hogg B, Keller PJ: The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel-releasing intrauterine devices. Contraception 2000, 61:365-368.